Background/Aims: Intravenous bisphosphonate therapy is the mainstay of medical treatment in osteogenesis imperfecta (OI) and has been shown to increase bone mass, decrease bone pain, improve mobility, and reduce the incidence of fractures. Sclerotic metaphyseal lines parallel to the growth plate are seen on long bone radiographs following cyclical intravenous therapy. These areas create stress risers within the bone that may act as foci for subsequent fractures as exemplified in this clinical case. Methods: An 8-year-old girl with OI sustained a distal radial fracture following 3 years of treatment with 6-monthly intravenous zoledronate. Her diagnosis, response to treatment, and subsequent fracture at a sclerotic metaphyseal line is described. Results: Peripheral quantitative computer tomography was used to characterise the presence of multiple stress risers at the distal forearm. Trabecular bone mineral density fluctuated from 34 to 126% compared to neighbouring 2-mm regions. Conclusion: There remain many unanswered questions about optimal bisphosphonate treatment regimens in children with OI. The formation of stress risers following intravenous bisphosphonate treatment raises the hypothesis that a more frequent and low-dose bisphosphonate regimen would provide more uniform dosing of bone in the growing child and reduce the likelihood of fractures compared to current treatment practices.

Keywords:
Osteogenesis imperfecta, Fracture, Bisphosphonates, Dual energy absorptiometry, Peripheral quantitative computer tomography
1.
Russell RG, Bisaz S, Fleisch H, Currey HL, Rubinstein HM, Dietz AA, Boussina I, Micheli A, Fallet G: Inorganic pyrophosphate in plasma, urine, and synovial fluid of patients with pyrophosphate arthropathy (chondrocalcinosis or pseudogout). Lancet 1970;2:899-902.
2.
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC: Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000;88:2961-2978.
3.
Luckman SP, Hughes DE, Coxon FP, Russell GG, Rogers MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998;13:581-589.
4.
Green JR, Muller K, Jaeggi KA: Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res 1994;9:745-751.
5.
Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A: Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002;42:1228-1236.
6.
Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M: Use of bisphosphonate therapy for osteoporosis in childhood and adolescence. J Paediatr Child Health 2003;39:88-92.
7.
Phillipi CA, Remmington T, Steiner RD: Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008;4:CD005088.
8.
Astrom E, Soderhall S: Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta. Acta Paediatr 1998;87:64-68.
9.
Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R: Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med 1998;339:947-952.
10.
Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH: Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000;85:1846-1850.
11.
Barros ER, Saraiva GL, de Oliveira TP, Lazaretti-Castro M: Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 2012;25:485-491.
12.
Tanvetyanon T, Stiff PJ: Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006;17:897-907.
13.
Manolopoulos KN, West A, Gittoes N: The paradox of prevention - bilateral atypical subtrochanteric fractures due to bisphosphonates in osteogenesis imperfecta. J Clin Endocrinol Metab 2013;98:871-872.
14.
Bachrach LK, Ward LM: Clinical review 1: Bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-409.
15.
Chilbule SK, Madhuri V: Complications of pamidronate therapy in paediatric osteoporosis. J Child Orthop 2012;6:37-43.
16.
Nicolaou N, Agrawal Y, Padman M, Fernandes JA, Bell MJ: Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates. J Child Orthop 2012;6:21-27.
17.
Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH: Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 2004;19:1779-1786.
18.
Christou J, Johnson AR, Hodgson TA: Bisphosphonate-related osteonecrosis of the jaws and its relevance to children - a review. Int J Paediatr Dent 2013;23:330-337.
19.
Rauch F, Travers R, Munns C, Glorieux FH: Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis. J Bone Miner Res 2004;19:1191-1193.
20.
Grissom LE, Harcke HT: Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 2003;33:226-229.
21.
Chen WF: Handbook of Structural Engineering. London, Taylor & Francis, 2010.
22.
Harcke HT, Stevenson KL, Kecskemethy HH, Bachrach SJ, Grissom LE: Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers. Pediatr Radiol 2012;42:76-81.
23.
Lu PW, Briody JN, Ogle GD, Morley K, Humphries IR, Allen J, Howman-Giles R, Sillence D, Cowell CT: Bone mineral density of total body, spine, and femoral neck in children and young adults: a cross-sectional and longitudinal study. J Bone Miner Res 1994;9:1451-1458.
24.
Rauch F: Bone biopsy: indications and methods. Endocr Dev 2009;16:49-57.
25.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
26.
Pace JM, Wiese M, Drenguis AS, Kuznetsova N, Leikin S, Schwarze U, Chen D, Mooney SH, Unger S, Byers PH: Defective C-propeptides of the proα2(I) chain of type I procollagen impede molecular assembly and result in osteogenesis imperfecta. J Biol Chem 2008;283:16061-16067.
27.
Zemel B, Bass S, Binkley T, Ducher G, Macdonald H, McKay H, Moyer-Mileur L, Shepherd J, Specker B, Ward K, Hans D: Peripheral quantitative computed tomography in children and adolescents: the 2007 ISCD pediatric official positions. J Clin Densitom 2008;11:59-74.
28.
Leibner ED, Mosheiff R, Safran O, Abu-Snieneh K, Liebergall M: Femoral fracture at the proximal end of an intramedullary supracondylar nail: a case report. Am J Orthop (Belle Mead, NJ) 1999;28:53-55.
29.
Rauch F, Cornibert S, Cheung M, Glorieux FH: Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 2007;40:821-827.
30.
Ward L, Tricco AC, Phuong P, Cranney A, Barrowman N, Gaboury I, Rauch F, Tugwell P, Moher D: Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;4:CD005324.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.